JCI Insight (Feb 2023)

Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype

  • Vinicius Vieira,
  • Nicholas Lim,
  • Alveera Singh,
  • Ellen Leitman,
  • Reena Dsouza,
  • Emily Adland,
  • Maximilian Muenchhoff,
  • Julia Roider,
  • Miguel Marin Lopez,
  • Julieta Carabelli,
  • Jennifer Giandhari,
  • Andreas Groll,
  • Pieter Jooste,
  • Julia G. Prado,
  • Christina Thobakgale,
  • Krista Dong,
  • Photini Kiepiela,
  • Andrew J. Prendergast,
  • Gareth Tudor-Williams,
  • John Frater,
  • Bruce D. Walker,
  • Thumbi Ndung’u,
  • Veron Ramsuran,
  • Alasdair Leslie,
  • Henrik N. Kløverpris,
  • Philip Goulder

Journal volume & issue
Vol. 8, no. 3

Abstract

Read online

HIV nonprogression despite persistent viremia is rare among adults who are naive to antiretroviral therapy (ART) but relatively common among ART-naive children. Previous studies indicate that ART-naive pediatric slow progressors (PSPs) adopt immune evasion strategies similar to those described in natural hosts of SIV. However, the mechanisms underlying this immunophenotype are not well understood. In a cohort of early-treated infants who underwent analytical treatment interruption (ATI) after 12 months of ART, expression of PD-1 on CD8+ T cells immediately before ATI was the main predictor of slow progression during ATI. PD-1+CD8+ T cell frequency was also negatively correlated with CCR5 and HLA-DR expression on CD4+ T cells and predicted stronger HIV-specific T lymphocyte responses. In the CD8+ T cell compartment of PSPs, we identified an enrichment of stem-like TCF-1+PD-1+ memory cells, whereas pediatric progressors and viremic adults had a terminally exhausted PD-1+CD39+ population. TCF-1+PD-1+ expression on CD8+ T cells was associated with higher proliferative activity and stronger Gag-specific effector functionality. These data prompted the hypothesis that the proliferative burst potential of stem-like HIV-specific cytotoxic cells could be exploited in therapeutic strategies to boost the antiviral response and facilitate remission in infants who received early ART with a preserved and nonexhausted T cell compartment.

Keywords